Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
504 questions in 57 reviews · Kidney and Transplant
current versionsNo studies 504 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mechanical thrombectomy vs continuous infusion Successful dialysis · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical thrombectomy vs pulse spray technique Technical success · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Mechanical thrombectomy vs continuous infusion Major adverse events · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Mechanical thrombectomy vs continuous infusion Death · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical thrombectomy vs continuous infusion Patency at 30 days · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical thrombectomy vs continuous infusion Failure · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical thrombectomy vs continuous infusion Access dysfunction · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical thrombectomy vs continuous infusion Successful dialysis · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical thrombectomy vs pulse spray technique Access dysfunction · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical thrombectomy vs continuous infusion Death · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Continuous Infusion vs pulse spray technique Failure · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Continuous Infusion vs pulse spray technique Access dysfunction · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Continuous Infusion vs pulse spray technique Successful dialysis · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Continuous Infusion vs pulse spray technique Major adverse events · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Continuous Infusion vs pulse spray technique Death · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Pharmacomechanical thrombolysis (Cragg® catheter) vs pulse spray technique Patency at 30 days · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical thrombectomy vs pulse spray technique Successful dialysis · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Pharmacomechanical thrombolysis (Cragg® catheter) vs pulse spray technique Failure · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Pharmacomechanical thrombolysis (Cragg® catheter) vs pulse spray technique Access dysfunction · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Pharmacomechanical thrombolysis (Cragg® catheter) vs pulse spray technique Successful dialysis · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Pharmacomechanical thrombolysis (Cragg® catheter) vs pulse spray technique Death · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical thrombectomy vs different types of endovascular interventions Access dysfunction · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical thrombectomy vs different types of endovascular interventions Successful dialysis · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical thrombectomy vs different types of endovascular interventions Death · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical thrombectomy vs pulse spray technique Minor adverse events · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical thrombectomy vs pulse spray technique Death · thrombosed haemodialysis arteriovenous fistulas and grafts Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts (2024) · Cochrane | no estimate extracted | NR | No studies |
Metformin vs active control Kidney failure · preventing the progression of CKD Metformin for preventing the progression of chronic kidney disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ High sodium dialysate vs standard sodium dialysate Duration of hospital stay ‐ not reported · haemodialysis patients Interventions for preventing haemodialysis dysequilibrium syndrome (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Sodium modelling vs slow dialysis Duration of hospital stay ‐ not reported · haemodialysis patients Interventions for preventing haemodialysis dysequilibrium syndrome (2024) · Cochrane | no estimate extracted | NR | No studies |
High vs low dose pegylated interferon alpha‐2a or alpha‐2b Death · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
High vs low dose pegylated interferon alpha‐2a or alpha‐2b End‐of‐treatment response · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
High vs low dose pegylated interferon alpha‐2a or alpha‐2b Treatment discontinuation · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
High vs low dose pegylated interferon alpha‐2a or alpha‐2b Adverse events · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
High vs low dose pegylated interferon alpha‐2a or alpha‐2b Serious adverse events · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Standard interferon plus ribavirin vs standard interferon alone Death · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Standard interferon plus ribavirin vs standard interferon alone Relapse(recurrence after stopping) · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Standard interferon plus ribavirin vs standard interferon alone End‐of‐treatment response · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Standard interferon plus ribavirin vs standard interferon alone Sustained virological response · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Standard interferon plus ribavirin vs standard interferon alone Adverse events · patients on HD with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Pegylated interferon plus ribavirin vs pegylated interferon alone Death · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Direct antivirals (grazoprevir and elbasvir) vs placebo Death · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Direct antivirals (grazoprevir and elbasvir) vs placebo Relapse · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Direct antivirals (grazoprevir and elbasvir) vs placebo Sustained virological response · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Direct antivirals (grazoprevir and elbasvir) vs placebo Treatment discontinuation · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Direct antivirals (grazoprevir and elbasvir) vs placebo Adverse events · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) Death · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) Relapse · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) Treatment discontinuation · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks) Adverse events · HD patients with HCV infection Interventions for dialysis patients with hepatitis C virus (HCV) infection (2023) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs angiotensin receptor blockers CVD events · adults with early (stage 1 to 3) non‐diabetic CKD Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to… (2023) · Cochrane | no estimate extracted | NR | No studies |